The Discounted Cash Flow (DCF) valuation of Reata Pharmaceuticals Inc (RETA) is (234.04) USD. With the latest stock price at 172.36 USD, the upside of Reata Pharmaceuticals Inc based on DCF is -235.8%.
Based on the latest price of 172.36 USD and our DCF valuation, Reata Pharmaceuticals Inc (RETA) is a sell. selling RETA stocks now will result in a potential gain of 235.8%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.6% - 9.5% | 8.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (560.97) - (152.27) | (234.04) |
| Upside | -425.5% - -188.3% | -235.8% |